Cancer represents an evolutionary process through which growing malignant populations
genetically diversify, leading to tumour progression, relapse and resistance to therapy. In …

From a clinical, morphological and molecular perspective, prostate cancer is a
heterogeneous disease. Primary prostate cancers are often multifocal, having …

Metastatic cancer is a major cause of death and is associated with poor treatment efficacy. A
better understanding of the characteristics of late-stage cancer is required to help adapt …

While mutations affecting protein-coding regions have been examined across many
cancers, structural variants at the genome-wide level are still poorly defined. Through …

Tumour formation involves random mutagenic events and positive evolutionary selection
acting on a subset of such events, referred to as driver mutations. A decade of careful …

The cancer transcriptome is remarkably complex, including low-abundance transcripts,
many not polyadenylated. To fully characterize the transcriptome of localized prostate …

The genomics of primary prostate cancer differ from those of metastatic castration-resistant
prostate cancer (mCRPC). We studied genomic aberrations in primary prostate cancer …

Mutations in the transcription factor FOXA1 define a unique subset of prostate cancers but
the functional consequences of these mutations and whether they confer gain or loss of …

Despite survival improvements achieved over the last two decades, prostate cancer remains
lethal at the metastatic castration-resistant stage (mCRPC) and new therapeutic approaches …

Abstract Background TP53, PTEN, and RB1 tumor suppressor genes (TSGs) are recurrently
altered in treatment-resistant prostate cancer. Cooperative loss of two or more TSGs may …